A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin
in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for
breast cancer patients. The hypothesis of this protocol is that the combined an active
angiogenesis agent to chemotherapy could enhance the pathological responce rate and further
benefit breast cancer patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hebei Medical University Fourth Hospital
Treatments:
Cyclophosphamide Docetaxel Endostar protein Epirubicin